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o r i g i n a l a r t i c l e
Increasing the Reliability of Fully Automated Surveillance for Central
Line–Associated Bloodstream Infections
Rachael E. Snyders, MPH, BSN, RN, CIC;1 Ashleigh J. Goris, MPH, BSN, RN, CIC;2 Kathleen A. Gase, MPH, CIC;1
Carole L. Leone, MSN, RN, CIC;1 Joshua A. Doherty, BS;1 Keith F. Woeltje, MD, PhD1,3
objective. To increase reliability of the algorithm used in our fully automated electronic surveillance system by adding rules to better
identify bloodstream infections secondary to other hospital-acquired infections.
methods. Intensive care unit (ICU) patients with positive blood cultures were reviewed. Central line–associated bloodstream infection
(CLABSI) determinations were based on 2 sources: routine surveillance by infection preventionists, and fully automated surveillance.
Discrepancies between the 2 sources were evaluated to determine root causes. Secondary infection sites were identiﬁed in most discrepant cases.
New rules to identify secondary sites were added to the algorithm and applied to this ICU population and a non-ICU population. Sensitivity,
speciﬁcity, predictive values, and kappa were calculated for the new models.
results. Of 643 positive ICU blood cultures reviewed, 68 (10.6%) were identiﬁed as central line–associated bloodstream infections by fully
automated electronic surveillance, whereas 38 (5.9%) were conﬁrmed by routine surveillance. New rules were tested to identify organisms as
central line–associated bloodstream infections if they did not meet one, or a combination of, the following: (I) matching organisms (by genus
and species) cultured from any other site; (II) any organisms cultured from sterile site; (III) any organisms cultured from skin/wound; (IV) any
organisms cultured from respiratory tract. The best-ﬁt model included new rules I and II when applied to positive blood cultures in an ICU
population. However, they didn’t improve performance of the algorithm when applied to positive blood cultures in a non-ICU population.
conclusion. Electronic surveillance system algorithms may need adjustment for speciﬁc populations.
Infect. Control Hosp. Epidemiol. 2015;36(12) :1396–1400
Surveillance for hospital-acquired infections has long been
established as an essential component in successful infection
prevention programs.1 Standardized surveillance, using
deﬁnitions provided by the Centers for Disease Control and
Prevention National Healthcare Safety Network (NHSN), has
aided the steady reduction of central line–associated bloodstream
infection (CLABSI) rates in intensive care units (ICUs).2
However, manual application of the NHSN CLABSI deﬁnitions
to positive blood culture results is often labor-intensive and
time-consuming for infection preventionists (IPs). For this
reason, manual CLABSI surveillance is often limited to ICUs.
CLABSI rates are similar in ICU and non-ICU patient
populations3–7; moreover, the number of patients in non-ICU
locations greatly surpasses those in ICU locations. Thus, in many
hospitals, there may actually be more patients with CLABSIs
outside the ICUs than in the ICUs.3,8 The widespread availability
of electronic patient and laboratory data offers the potential for
electronic surveillance of CLABSIs outside of the ICUs.9
A semiautomated electronic surveillance system has been used
in BJC HealthCare to facilitate identiﬁcation of positive blood
culture results and potential ICU CLABSIs for 7 years10 and is
now part of our routine ICU surveillance. A fully automated
electronic surveillance system has been used to track non-ICU
CLABSIs for 5 years.9 The algorithm used in this surveillance
system was designed to be as consistent with the NHSN CLABSI
deﬁnition as possible given that there is no formal guidance from
NHSN on how best to conduct fully electronic surveillance for
CLABSIs. Feedback from IPs is that if the fully automated
electronic surveillance system were better able to identify and
eliminate secondary bloodstream infections (BSIs), this would
increase speciﬁcity. The objective of this study was to increase the
reliability of the algorithm used in our fully automated electronic
surveillance system by incorporating new rules to better identify
BSIs that are secondary to other healthcare-associated infections,
as deﬁned by NHSN.
methods
BJC HealthCare is a large, nonproﬁt healthcare organization
comprising 11 acute care facilities and multiple community
Afﬁliations: 1. Center for Clinical Excellence, BJC HealthCare, St. Louis, Missouri; 2. Infection Prevention and Control, Missouri Baptist Medical Center,
St. Louis, Missouri; 3. Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
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health locations, serving urban, suburban, and rural commu-
nities in Missouri and Illinois. Patients in 17 ICUs with
positive culture results of blood drawn from January 1 through
June 30, 2011, were identiﬁed from the BJC HealthCare
informatics database. Medical, surgical, cardiothoracic surgical,
and neurosurgical ICUs were represented from 8 of the
11 hospitals; pediatric and neonatal ICUs were excluded. These
patients were chosen for the study because IPs conducted pro-
spective CLABSI surveillance in this population using the NHSN
deﬁnitions. This afforded us the opportunity to compare
CLABSIs identiﬁed from routine surveillance with those identi-
ﬁed from the fully automated electronic surveillance system.
Positive blood culture results are considered CLABSIs by the
existing fully automated electronic surveillance algorithm if
they meet the following rules:
1. Blood cultures must be collected more than 48 hours after
hospital admission.
2. Central line must be in place at the time of culture or
discontinued within 48 hours prior to the culture.
3. Blood cultures with organism(s) that are common skin
contaminants, such as coagulase-negative staphylococcus,
must have a second culture with the same organism(s)
within 3 calendar days, and have clinical documentation of
a fever (temperature, >38.0°C) within 48 hours of the ﬁrst
blood culture collection date.
4. Matching organisms from different blood cultures are
considered the same CLABSI episode if they were isolated
within 14 days of one another.
5. Two or more different organisms from different blood
cultures are considered the same CLABSI episode if they
were isolated within 7 days of one another.
6. Matching organisms seen in both a nonblood specimen and
blood culture, where the nonblood specimen was collected
within a window beginning 21 days prior and ending 7 days
after the blood culture, are used to exclude the blood
culture from being a CLABSI episode; these are considered
secondary BSIs.
Positive blood culture results were classiﬁed as discrepant if
they were conﬁrmed as a CLABSI by either routine surveil-
lance or fully automated electronic surveillance, but not both.
All discrepant cases were evaluated by 3 IPs credentialed with
Certiﬁcation in Infection Prevention and Control to determine
root causes of the discrepancies. The root causes were then
used to brainstorm proposed new rules to include in the
algorithm. Owing to the fact that the algorithm rules are
applied to each organism in a blood culture separately, all
analysis was performed at the level of organism, rather than at
the patient level, accounting for patients with polymicrobial
bacteremias. Sensitivity, speciﬁcity, positive predictive value,
negative predictive value, and kappa scores were used to eval-
uate the proposed new rules.
Evaluation of the proposed new rules was ﬁrst performed
with our aforementioned original ICU study population. Next,
evaluation of the proposed new rules was performed with a
non-ICU study population. This population included patients
in non-ICUs with positive culture results of blood drawn from
January 1 through December 31, 2012, identiﬁed from the BJC
HealthCare informatics database. Various types of non-ICUs
were represented from 9 of the 11 acute care facilities,
including medical, surgical, oncology, pediatric, and numer-
ous other specialty units. These blood cultures were previously
evaluated for the presence or absence of CLABSI events by
routine surveillance by an IP credentialed with a Certiﬁcation
in Infection Prevention and Control.
results
During the study period, 643 blood cultures from 518 ICU
patients were reviewed. Routine surveillance by a hospital-
based IP identiﬁed 38 organisms (5.9%) as CLABSIs; fully
automated electronic surveillance identiﬁed 68 organisms
(10.6%) as CLABSIs (Table 1). A total of 46 organisms were
discordantly called by routine and fully automated electronic
surveillance methods, most of which were called CLABSIs by
the fully automated electronic surveillance system but not by
the IP. Secondary infection sites that did not meet rule 5 of the
existing algorithm were identiﬁed in most discrepant cases. On
the basis of the ﬁndings, several new rules to identify secondary
sites were investigated for inclusion into the existing algorithm
of our fully automated electronic surveillance system.
table 1. Comparison of Routine Surveillance and Fully Automated Electronic Surveillance by Number of Organisms Conﬁrmed as
CLABSIs–ICU Only
Routine Surveillance
Fully Automated Surveillance Existing Algorithm CLABSIs No CLABSIs
CLABSIs 30 38
No CLABSIs 8 567
Fully Automated Surveillance Proposed New Algorithm (E + Ia + II) CLABSIs No CLABSIs
CLABSIs 31 23
No CLABSIs 7 582
NOTE. CLABSI, central line–associated bloodstream infection; ICU, intensive care unit.
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Each of the new rules below, if met within 14 days before or
after the positive blood culture, would classify an organism as a
secondary BSI rather than a CLABSI.
I. Matching organisms, by genus and species, cultured from
any other site
Ia. Excluding yeast if cultured from the respiratory tract, skin,
and/or wound(s)
Ib. Allows matching for yeast at the species level if cultured
from any other site (ie, Candida albicans cultured from the
blood would “match” any Candida spp. cultured from the
urine), while still excluding yeast cultured from the
respiratory tract, skin, and/or wound(s)
II. Any organisms cultured from a sterile site
III. Any organisms cultured from skin and/or wound(s)
IV. Any organisms cultured from the respiratory tract
Rules I, Ia, and Ib were each included individually with the
rules of the existing algorithm and applied to the ICU study
population. They were also tested in various combinations
with rules II, III, and IV with the rules of the existing algo-
rithm. The addition of rules I, Ia, and Ib individually improved
the performance of the algorithm in the ICU population, as
well as many of the aggregate rule sets. The best-ﬁt model
included rules Ia and II, decreased the discrepant organisms
from 46 to 30 (Table 1), and increased the kappa score from
0.530 to 0.650 (Table 2). Importantly, adding rules Ia and II to
the algorithm increased the positive predictive value from
44.1% to 57.4% without adversely affecting the negative
predictive value, which was already at 98%.
The best-ﬁt model was then applied to the non-ICU study
population of 796 blood cultures from 563 patients. The
existing algorithm identiﬁed 515 organisms (64.7%) as
CLABSIs, while routine surveillance identiﬁed 428 organisms
(53.8%) as CLABSIs (speciﬁcity, 71.4%; sensitivity, 96.0%)
(Table 3). Applying the best-ﬁt model resulted in the identi-
ﬁcation of 489 organisms (61.4%) as CLABSIs; this improved
the speciﬁcity slightly to 75.7%, but at the cost of lower
sensitivity (92.5%), resulting in an overall lower kappa score
(0.680 vs 0.689) (Table 4). Application of other combinations
of rules did not measurably improve performance of the
algorithm (data not shown).
discussion
Adding new rules designed to identify secondary BSIs to the
algorithm increased the reliability of our fully automated
electronic surveillance system when applied to ICU patients,
but adversely impacted the negative predictive value and kappa
score when applied to non-ICU patients. We initially chose to
table 2. Performance of New Rules and Aggregate Rule Sets for CLABSI Prediction–ICU Only
Organisms predicted to be CLABSIs N (%) Sensitivity % Speciﬁcity % PPV % NPV % Kappa
Existing Algorithm (E) 68 (10.6) 78.9 93.7 44.1 98.6 .530
Proposed new secondary rules (all represent timing within ± 14 days of positive blood culture)
E + Rule I 59 (9.2) 73.7 94.9 47.4 98.3 .545
E + Rule Ia 62 (9.6) 81.6 94.9 50.0 98.8 .590
E + Rule Ib 56 (8.7) 71.0 95.2 48.2 98.1 .542
E + Rule I + Rule II 51 (7.9) 73.7 96.2 54.9 98.3 .602
E + Rule Ia + Rule II 54 (8.4) 81.6 96.2 57.4 98.8 .650
E + Rule Ib + Rule II 49 (7.6) 71.0 96.4 55.1 98.1 .594
E + Rule I + Rule II + Rule III 44 (6.8) 60.5 96.5 52.3 97.5 .531
E + Rule Ia + Rule II + Rule III 46 (7.1) 65.8 96.5 54.3 97.8 .567
NOTE. CLABSI, central line–associated bloodstream infection; ICU, intensive care unit; NPV, negative predictive value; PPV, positive
predictive value.
table 3. Comparison of Routine Surveillance and Fully Automated Electronic Surveillance by Number of Organisms Conﬁrmed as
CLABSIs–Non-ICU Only
Routine Surveillance
Fully Automated Surveillance Existing Algorithm CLABSIs No CLABSIs
CLABSIs 411 104
No CLABSIs 17 264
Fully Automated Surveillance Proposed New Algorithm (E + Ia + II) CLABSIs No CLABSIs
CLABSIs 396 93
No CLABSIs 32 275
NOTE. CLABSI, central line–associated bloodstream infection; ICU, intensive care unit.
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develop the proposed new rules based on an ICU patient
population, rather than a non-ICU patient population,
because we had access to detailed surveillance data. This
allowed us to classify and examine the discrepancies between
the 2 surveillance methods. Given that CLABSI rates are
similar in ICU and non-ICU patients,3–7 we believed it was a
reasonable population as well.
The premise of rule I was to capture other site cultures in a
different timeframe than the existing algorithm. Rule I allowed
for other site cultures to be considered within 14 days before or
after the positive blood culture result as opposed to the existing
algorithm; the existing algorithm allowed 7 days after the
blood culture, but allowed up to 21 days before the blood
culture, which was thought to be too expansive. Rule Ia was
designed to ensure that yeast species cultured from the
respiratory tract, skin, or wounds did not negate a primary
CLABSI with candidemia, given that yeast cultured from these
sites often represents colonization rather than infection. The
addition of rule II to rule Ia increased the kappa score from
0.590 to 0.650 in the ICU study population, highlighting the
importance of considering polymicrobial sterile site infections
as the primary site of a bacteremia, as opposed to the central
line in place. Accounting for potential skin, wound, soft-tissue,
and respiratory infections with nonmatching organisms, in an
effort to identify secondary BSIs, did not add reliability or
improve the algorithm.
Addition of these rules did not improve performance of the
fully automated electronic surveillance system for patients
outside of the ICU. The design of the current study did not
allow for a detailed investigation of the reasons. It is plausible
that non-ICU patients with secondary BSIs have different
characteristics in general. It is also plausible that clinicians’
patterns of obtaining samples for culture differ between non-
ICU settings and ICU settings. As semiautomated and fully
automated electronic surveillance systems are reﬁned, it may
be necessary to implement different algorithms depending on
the location of patient care in order to optimize the balance of
sensitivity and speciﬁcity.
There is widespread and increasing interest in fully automated
electronic surveillance for healthcare-associated infections;
however, there remain several large issues that need to be
addressed before this can be accomplished.5,11,12 Similar to pre-
vious studies, our fully automated electronic surveillance system
likely overestimates the number of CLABSIs. A major limitation
to using fully automated electronic surveillance for CLABSIs is
the inaccessibility to radiographic imaging reports or other
diagnostic criteria that can be used to identify secondary site
infections during routine surveillance, such as narrative physician
or nursing documentation. Improvements to electronic medical
records that ensure consistent documentation of these types of
criteria may further enhance automated surveillance.
Fully automated electronic surveillance offers great poten-
tial for performing housewide CLABSI surveillance without a
dramatic increase in resources.9 Since our initial work, NHSN
has updated the CLABSI deﬁnition, including a transition
from hours to calendar days (eg, 48 hours after admission
vs 2 calendar days after admission to quantify a potential
healthcare-associated infection, among others). We will be
updating both our semiautomated and fully automated
electronic surveillance systems to incorporate these changes.
Although we were not able to improve the performance of the
algorithm used in our fully automated electronic surveillance
system to identify non-ICU secondary BSIs in this study,
the new Centers for Medicare and Medicaid Services mandate
for CLABSI surveillance in non-ICU medical and surgical
units13 will provide us with a population of IP-validated
CLABSIs that we can use to further reﬁne our algorithms. In
addition, more clinical data are becoming available electro-
nically for use in decision support algorithms. This will allow
us to expand our efforts to improve our algorithms both for
semiautomated and fully automated electronic surveillance
systems.
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